Solriamfetol improves symptoms in myalgic encephalomyelitis/chronic fatigue
The Brown University Psychopharmacology Updateopenaire +1 more source
Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation [PDF]
Journal of Pharmaceutical Analysis, 2023 Given that impurities may affect the quality and safety of drug products, impurity identification and profiling is an integral part of drug quality control and is particularly important for newly developed medications such as solriamfetol, which is used ...
Nafisah Al-Rifai +2 more
exaly +7 more sources
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. [PDF]
Hum Psychopharmacol, 2023 AbstractObjectiveTo evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy.MethodsIn this randomised, double‐blind, placebo‐controlled, crossover study, driving performance during a 1 h on‐road driving test was assessed at 2 and 6 h post‐dose following 7 ...
Vinckenbosch F +8 more
europepmc +9 more sources
A randomized study of solriamfetol for excessive sleepiness in narcolepsy [PDF]
Annals of Neurology, 2019 ObjectiveSolriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.MethodsPatients with narcolepsy with mean sleep latency <25 minutes on the Maintenance of Wakefulness Test (MWT), Epworth ...
Thorpy M. J. +11 more
core +6 more sources
Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial [PDF]
Frontiers in MedicineIntroductionWake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA).
Fen Wang +7 more
doaj +2 more sources
Solriamfetol for the Treatment of Excessive Sleepiness in OSA [PDF]
Chest, 2019 International audience ; Background: Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA.Methods: After 2 weeks of clinical titration (n = 174) and 2 weeks of stable dose ...
Patrick J. Strollo +39 more
openaire +3 more sources
Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. [PDF]
PLoS ONEPurposeExcessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents.
Lingling Wu, Kaijian Zhu
doaj +2 more sources
Pharmacological and non-pharmacological methods of inducing wakefulness activate distinct neural populations in the mouse brain. [PDF]
PLoS BiologyA large body of data indicate that the aminergic, cholinergic and hypocretin/orexin neurons are responsible for inducing wakefulness. However, recent data showed that other systems might also play a key role.
Renato Maciel +8 more
doaj +2 more sources
Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]
BMC NeurologyBackground As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan +5 more
doaj +2 more sources
0763 Effects Of Solriamfetol On Driving Performance In Participants With Narcolepsy [PDF]
Sleep, 2020 Abstract Introduction Patients with narcolepsy have an increased risk of automobile accidents. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the US (Sunosi®) for adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-150 mg/day). This study evaluated
Vinckenbosch, F. +8 more
openaire +3 more sources